Cassava presents promising preclinical simufilam data at tsc alliance meeting

Data show that simufilam reduced seizure activity in a preclinical mouse model presentation also highlights favorable human safety data from 1,929 patient phase 3 program austin, texas, june 30, 2025 (globe newswire) -- cassava sciences, inc. (nasdaq: sava, “cassava”, the “company”), a clinical-stage biotechnology company focused on developing novel, investigational treatments for central nervous system (cns) disorders, today announced that the company presented a poster at the tsc international research conference (tsc 2025) held june 26-28, 2025 in bethesda, md. the poster, available on the company website via this link, detailed two important observations that support cassava's plan to initiate human clinical studies in h1 2026 to evaluate simufilam as a treatment for tuberous sclerosis complex (tsc)-related epilepsy: preclinical proof-of-concept: treatment with simufilam alleviated neuronal abnormalities and reduced seizure frequency by 60% compared to vehicle in a mouse model of focal onset seizures.
SAVA Ratings Summary
SAVA Quant Ranking